Publicly available resource monitors the development of therapies to treat and prevent disease
WASHINGTON, March 18, 2020 — The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.
“We seek to accelerate efforts to find new treatments or vaccines, amplify what’s working, hold the system and its players accountable, and expand the global discussion about how to create durable, long term solutions,” says Esther Krofah, executive director of FasterCures. “COVID-19 is putting that approach to the test. We hope to be a resource promoting effective approaches and strategies."
The Milken Institute COVID-19 vaccine development and treatment tracker is compiled from publicly available sources and will be updated regularly. It will grow to include FDA-approved indications where applicable, as well as basic information about the focus of each clinical trial.
The Milken Institute welcomes input on new treatments and vaccines in development. Please email [email protected] with tips.
Our understanding of the science of cancer has increased exponentially in the last 15 years and continues to advance rapidly with new lifesaving treatments being discovered daily. Yet our infrastructure for delivering cancer care to our...
Employers seek to support their employees while normalizing a whole-person approach to substance use disorders (SUD). The response to addiction and the opioid crisis requires a whole-of-society approach, including employers of all sizes...
In This Newsletter New FasterCures Team Member Policy Updates Events and Convenings Recap FasterCures in the Community FasterCures in the Media Upcoming Event: Global Conference Stay in the Know New FasterCures Team Member Please join us in...
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Patient preferences and insights are increasingly considered throughout the medical product life cycle in addition to clinical outcomes. We know that incorporating patient preferences in the product life cycle can create meaningful results...
Patient preferences and insights are increasingly considered throughout the medical product life cycle in addition to clinical outcomes. We know that incorporating patient preferences in the product...
The 26th annual Milken Institute Global Conference convened the best minds in the world to tackle its most urgent challenges and realize its most exciting opportunities. Throughout the four-day event, our health teams curated nearly three...
Cell and gene therapies are a new category of medicines transforming how we treat and potentially cure disease. Both cell and gene therapies seek to modify genetic material to fight disease. Cell therapies involve cultivating or modifying...
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical innovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not...
FasterCures wants to ensure that the lessons of the COVID-19 crisis are not lost once the current urgency subsides — not only for combating future infectious diseases, but for conducting every other aspect of biomedical innovation...
FasterCures, a center of the Milken Institute, designed this guide for patient advocacy organizations that are interested in hosting, or are currently planning, an externally led patient-focused drug development (PFDD) meeting. We have...